EUCTR2010-024211-13-DE进行中（未招募）不适用
ong term, single-arm, open-label extension study of the MUSIC study to assess the safety and tolerability of macitentan in patients with idiopathic pulmonary fibrosis - MUSIC O
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 178
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Signed informed consent prior to initiation of any study-related procedure.
- •- Patients with IPF and having completed the double-blind AC-055B201/MUSIC study as scheduled, i.e., having remained in the study until the sponsor-declared end-of study, whether or not study treatment was prematurely discontinued.
- •- Women of childbearing potential must have a negative pre-treatment serum pregnancy test and must use a reliable method of contraception during study treatment and for at least 28 days after study treatment termination.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 65
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 113
排除标准
- •- Any major violation of protocol AC-055B201/MUSIC.
- •- Premature discontinuation of study treatment during the AC-055B201/MUSIC study due to an adverse event (AE) assessed as related to the use of macitentan, excluding events of IPF worsening.
- •- Pregnancy or breast-feeding.
- •- AST and/or ALT > 3 times the upper limit of the normal range.
- •- Any known factor or disease that might interfere with treatment compliance, study conduct or interpretation of the results, such as drug or alcohol dependence or psychiatric disease.
- •- Known hypersensitivity to drugs of the same class as macitentan, or any of the excipients.
研究者
相似试验
进行中（未招募）
1 期
Study to evaluate if macitentan is safe and tolerable enough to be usedfor treatment of idiopathic pulmonary fibrosis, following the MUSICstudyEUCTR2010-024211-13-ESACTELION Pharmaceuticals Ltd.178
进行中（未招募）
1 期
ong-term study to evaluate if macitentan is safe, tolerable and efficient enough to be used for treatment of Eisenmenger syndromeMedDRA version: 17.1Level: PTClassification code 10058554Term: Eisenmenger's syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEisenmenger SyndromeEUCTR2012-004411-31-ROActelion Pharmaceuticals Ltd.217
进行中（未招募）
1 期
ong-term study to evaluate if macitentan is safe, tolerable and efficient enough to be used for treatment of Eisenmenger syndromeMedDRA version: 18.1 Level: LLT Classification code 10058554 Term: Eisenmenger's syndrome System Organ Class: 100000004850Eisenmenger SyndromeEUCTR2012-004411-31-PTActelion Pharmaceuticals Ltd217
进行中（未招募）
1 期
ong-term study to evaluate if macitentan is safe, tolerable and efficient enough to be used for treatment of Eisenmenger syndromeEisenmenger SyndromeEUCTR2012-004411-31-PLActelion Pharmaceuticals Ltd.220
进行中（未招募）
1 期
ong-term study to evaluate if macitentan is safe, tolerable and efficient enough to be used for treatment of Eisenmenger syndromeMedDRA version: 18.0Level: PTClassification code 10058554Term: Eisenmenger's syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEisenmenger SyndromeEUCTR2012-004411-31-GRActelion Pharmaceuticals Ltd.220